Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
I have a small position average at .70.Letting it play out. there was an R/S proposed,which was voted down by shareholders. Monday we will probably end up with 2x the AS count. I’m riding that out, their new CFO Chris Stewart coming over from Tesla. Amazing new CMO, Alka Chaubey from Perkin Elmer ( who has 6 mil market cap ). No one else has this cytogenics tech and it is heavily patent protected. Finds genome variants that can not be found elsewhere. I expect a Monday dip with the new shares added. Also think this co is on the verge of something very big . There are the eyes of bigger pharma players on it.
I said 6 mil market cap for Perkin Elmer, I meant 6 BILLION. Bottom line there is, there are some key people leaving large companies to come over to little old Bionano, something is coming imo